U.S. trends of anti-vascular endothelial growth factor use from 2017-2023: An analysis of medicare, medicaid, and commercial insurance.

PLoS One · 2026 · PMC12798985 · PMID 41529044

Europe PMC DOI

hedged sentence

0.0260

closest p · 0.5× alpha

0.0260

boldest claim

The sentences

marginally significantp = 0.026actually significant

Medicaid patients had a marginally significant difference in use of bevacizumab (M = 19.9/100000 OE, SD = 7.32) and aflibercept 2 mg (16.1/100000 OE, SD = 7.22) [t(6)]=2.95, p = 0.026].

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.